Soft Tissue Augmentation Using Sculptra

ABSTRACT

Sculptra (poly-L-lactic acid) as of August 2004 has been approved by the U.S. Food and Drug Administration as the first injectable facial volumizer in the treatment of lipoatrophy. Lipoatrophy is often seen in HIV-positive patients and is felt to be multifactorial. This article reviews European and U.S. clinical study data and summarize treatment technique for both on label and off-label use.

KEYWORDS

Poly-L-lactic acid - Sculptra - facial fat loss - lipoatrophy - volume replacement

REFERENCES

• 1 Brady J M, Cutright D E, Miller R A, Barristone G C. Resorption rate, route, route of elimination, and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat.  J Biomed Mater Res. 1973;  7 155-166
• 2 Cutright D E, Perez B, Beasley III J D, Larson W J, Posey W R. Degradation rates of polymers and copolymers of polylactic and polyglycolic acids.  Oral Surg Oral Med Oral Pathol. 1974;  37 142-152
• 3 Sattler G. Long-lasting results with polylactic acid.  Derm. 2003;  9 422-423
• 4 Amard & Saint Marc .Polylactic acid in the treatment of HIV-associated lipoatrophy. Second Lipodystrophy Workshop, Toronto, Canada; September 2000
• 5 Mest D M, Humble G. Hermosa Beach, California, Current IDE#G020113. 
• 6 Lafaurie M. Dolivio, St. Louis Hospital, Paris, France Treatment of lipoatrophy with injections of polylactic acid. Tenth Conference for Retrovirus and Opportunistic Infection. February 2003
• 7 Moyle G J, Lysakova L, Brown S et al.. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection.  HIV Med. 2004;  5 82-87
• 8 Mest D, Humble G. Safety and efficiency of intradermal poly-L-lactic acid (Sculptura) injections for patients with HIV associated facial lipoatrophy.  Antivir Ther. 2004;  9 L36
• 9 Engelhard P, Knies M. Safety and efficacy of New-Fill® (polylactic acid) in the treatment of HIV-associated lipoatrophy of the face (HALF). XIV International AIDS Conference Barcelona, Spain; July 7-12, 2002
• 10 Sommer B. Crystalline polyactic acid (New-Fill): current handling guidelines. Skin 2004 15
• 11 Vleggaar D, Bauer U. Facial enhancement and the European experience with poly-L-lactic acid.  J Drugs Dermatol. 2004;  3 542-547